Ticagrelor Alone Cuts Bleeding Without More Events Post-PCI

Ticagrelor monotherapy safely cut bleeding by more than half after intervention for acute coronary syndrome, without an increase in MACCE, in the ULTIMATE-DAPT trial.

Related Keywords

United Kingdom ,Nanjing ,Jiangsu ,China ,Vienna ,Wien ,Austria ,Italy ,New York ,United States ,Virginia ,Pakistan ,Gloriam Steiner Gager ,Shao Liang Chen ,Jolantam Siller Matula ,Wayne Batchelor ,Icahn School Of Medicine ,Vascular Institute ,Academic Research Consortium ,University Of Vienna ,Mount Sinai Health System ,Duke University ,American College Of Cardiology Scientific Session ,International Society On Thrombosis ,New York City ,Icahn School ,American College ,Cardiology Scientific Session ,Nanjing Medical University ,Nanjing First Hospital ,Bleeding Academic Research Consortium ,Occluded Arteries ,International Society ,Inova Heart ,Medical University ,Acute Coronary Syndrome Acs ,Aspirin ,Acetylsalicylic Acid ,Thromboembolism ,Cardiac Surgeries ,Cardiac Surgery ,Stroke Cerebrovascular Accident Cva ,Hemorrhage ,Bleeding ,Stent ,Drug Eluting Stent ,Myocardial Infarction ,Target Vessel Revascularization ,Vr Target Vessel Revascularization ,Thrombosis ,Cv Risk ,